keyword
MENU ▼
Read by QxMD icon Read
search

ebola virus disease

keyword
https://www.readbyqxmd.com/read/28732038/analysis-of-patient-data-from-laboratories-during-the-ebola-virus-disease-outbreak-in-liberia-april-2014-to-march-2015
#1
Yuki Furuse, Mosoka Fallah, Hitoshi Oshitani, Ling Kituyi, Nuha Mahmoud, Emmanuel Musa, Alex Gasasira, Tolbert Nyenswah, Bernice Dahn, Luke Bawo
An outbreak of Ebola virus disease (EVD) in Liberia began in March 2014 and ended in January 2016. Epidemiological information on the EVD cases was collected and managed nationally; however, collection and management of the data were challenging at the time because surveillance and reporting systems malfunctioned during the outbreak. EVD diagnostic laboratories, however, were able to register basic demographic and clinical information of patients more systematically. Here we present data on 16,370 laboratory samples that were tested between April 4, 2014 and March 29, 2015...
July 21, 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28729706/sudan-ebolavirus-long-recovered-survivors-produce-gp-specific-abs-that-are-of-the-igg1-subclass-and-preferentially-bind-fc%C3%AE-ri
#2
Olga Radinsky, Avishay Edri, Michael Brusilovsky, Shlomit Fedida-Metula, Ariel Sobarzo, Orly Gershoni-Yahalom, Julius Lutwama, John Dye, Leslie Lobel, Angel Porgador
Ebolavirus is a highly lethal pathogen, causing a severe hemorrhagic disease with a high fatality rate. To better understand immune correlates of protection by virus specific IgG, we investigated the evolution of the Fcγ receptors (FcγRs)-activating capabilities of antiviral IgG in serum samples of long recovered survivors. To this end, longitudinal serum samples from survivors of Sudan ebolavirus (SUDV) infection, studied over years, were examined for the presence of Ebola-GP specific IgG subclasses, and for their binding to FcγRs...
July 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28726614/occupational-exposures-to-ebola-virus-in-ebola-treatment-center-conakry-guinea
#3
Hélène Savini, Frédéric Janvier, Ludovic Karkowski, Magali Billhot, Marc Aletti, Julien Bordes, Fassou Koulibaly, Pierre-Yves Cordier, Jean-Marie Cournac, Nancy Maugey, Nicolas Gagnon, Jean Cotte, Audrey Cambon, Christine Mac Nab, Sophie Moroge, Claire Rousseau, Vincent Foissaud, Thierry De Greslan, Hervé Granier, Gilles Cellarier, Eric Valade, Philippe Kraemer, Philippe Alla, Audrey Mérens, Emmanuel Sagui, Thierry Carmoi, Christophe Rapp
We report 77 cases of occupational exposures for 57 healthcare workers at the Ebola Treatment Center in Conakry, Guinea, during the Ebola virus disease outbreak in 2014-2015. Despite the high incidence of 3.5 occupational exposures/healthcare worker/year, only 18% of workers were at high risk for transmission, and no infections occurred.
August 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/28726603/clinical-laboratory-values-as-early-indicators-of-ebola-virus-infection-in-nonhuman-primates
#4
Ronald B Reisler, Chenggang Yu, Michael J Donofrio, Travis K Warren, Jay B Wells, Kelly S Stuthman, Nicole L Garza, Sean A Vantongeren, Ginger C Donnelly, Christopher D Kane, Mark G Kortepeter, Sina Bavari, Anthony P Cardile
The Ebola virus (EBOV) outbreak in West Africa during 2013-2016 demonstrated the need to improve Ebola virus disease (EVD) diagnostics and standards of care. This retrospective study compared laboratory values and clinical features of 3 nonhuman primate models of lethal EVD to assess associations with improved survival time. In addition, the study identified laboratory values useful as predictors of survival, surrogates for EBOV viral loads, and triggers for initiation of therapeutic interventions in these nonhuman primate models...
August 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/28725019/high-dose-sertraline-monotherapy-fails-to-protect-rhesus-macaques-from-lethal-challenge-with-ebola-virus-makona
#5
Anna N Honko, Joshua C Johnson, Jonathan S Marchand, Louis Huzella, Ricky D Adams, Nicholas Oberlander, Lisa M Torzewski, Richard S Bennett, Lisa E Hensley, Peter B Jahrling, Gene G Olinger
The recent epidemic of Ebola virus disease in West Africa resulted in an unprecedented number of cases and deaths. Due to the scope of the outbreak combined with the lack of available approved treatment options, there was strong motivation to investigate any potential drug which had existing data reporting anti-Ebola activity. Drugs with demonstrated antiviral activity in the nonhuman primate models already approved for another indication or for which there was existing safety data were considered to be priorities for evaluation by the World Health Organization...
July 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28723900/the-natural-history-of-acute-ebola-virus-disease-among-patients-managed-in-five-ebola-treatment-units-in-west-africa-a-retrospective-cohort-study
#6
Kelly Skrable, Reshma Roshania, Michaela Mallow, Vanessa Wolfman, Matthew Siakor, Adam C Levine
INTRODUCTION: Previous studies of Ebola Virus Disease (EVD) have focused on clinical symptoms and Ebola virus (EBOV) cycle threshold (CT) values recorded at patient triage. Our study explores EVD symptoms and EBOV CT values from onset of illness to recovery or death in a diverse population of patients. METHODOLOGY/PRINCIPAL FINDINGS: We analyzed clinical care data from EBOV positive patients admitted to five Ebola treatment units in West Africa from 2014-2015. Prevalence of clinical signs/symptoms and CT values were explored using descriptive statistics...
July 19, 2017: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/28722621/health-care-access-during-the-ebola-virus-epidemic-in-liberia
#7
Patricia A McQuilkin, Kanagasabai Udhayashankar, Michelle Niescierenko, Louise Maranda
The Ebola virus disease (EVD) epidemic, which began in West Africa in December 2013, claimed more than 11,000 lives, with more than 4,800 of these deaths occurring in Liberia. The epidemic had an additional effect of paralyzing the health-care systems in affected countries, which led to even greater mortality and morbidity. Little is known about the impact that the epidemic had on the provision of basic health care. During the period from March to May 2015, we undertook a nationwide, community-based survey to learn more about health-care access during the EVD epidemic in Liberia...
July 10, 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28722548/the-change-makers-of-west-africa
#8
EDITORIAL
Sue Godt, Sharmila Mhatre, Anne-Marie Schryer-Roy
West Africa was the focus of global attention during the Ebola virus disease outbreak, when systemic health system weaknesses compounded a serious emergency and complicated response efforts. Following the crisis, calls were made to strengthen health systems, but investments to date have fallen short of delivering the support needed to build strong health systems able to prevent and manage future outbreaks.In part, this reality serves to highlight the shortcomings of the solutions being repeatedly prioritised by external funders and experts, solutions that often fail to consider the wealth of West African evidence and actors actively working to strengthen the leadership and health systems needed to drive and sustainably improve national health outcomes...
July 12, 2017: Health Research Policy and Systems
https://www.readbyqxmd.com/read/28721309/retinal-pigment-epithelial-cells-are-a-potential-reservoir-for-ebola-virus-in-the-human-eye
#9
Justine R Smith, Shawn Todd, Liam M Ashander, Theodosia Charitou, Yuefang Ma, Steven Yeh, Ian Crozier, Michael Z Michael, Binoy Appukuttan, Keryn A Williams, David J Lynn, Glenn A Marsh
PURPOSE: Success of Ebola virus (EBOV) as a human pathogen relates at the molecular level primarily to blockade the host cell type I interferon (IFN) antiviral response. Most individuals who survive Ebola virus disease (EVD) develop a chronic disease syndrome: approximately one-quarter of survivors suffer from uveitis, which has been associated with presence of EBOV within the eye. Clinical observations of post-Ebola uveitis indicate involvement of retinal pigment epithelial cells. METHODS: We inoculated ARPE-19 human retinal pigment epithelial cells with EBOV, and followed course of infection by immunocytochemistry and measurement of titer in culture supernatant...
July 2017: Translational Vision Science & Technology
https://www.readbyqxmd.com/read/28721172/contact-tracing-following-outbreak-of-ebola-virus-disease-in-urban-settings-in-nigeria
#10
Olufunmilayo Ibitola Fawole, Mahmood Muazu Dalhat, Meeyoung Park, Casey Daniel Hall, Patrick Mboya Nguku, Peter Adebayo Adewuyi
An outbreak of Ebola virus disease occurred in Nigeria between July and September 2014. Contact tracing commenced in Lagos, and extended to Port Harcourt and Enugu as the outbreak continued to spread. A total of 899 contacts were traced. Contact tracing enhanced immediate identification of symptomatic contacts, some of whom eventually became cases. Contact tracing could be challenging in urban cities. However, use of electronic technology, adequate logistics, and highly skilled personnel enhanced the tracing of contacts to facilitate the successful containment of the outbreak...
2017: Pan African Medical Journal
https://www.readbyqxmd.com/read/28719299/conventional-wisdom-versus-actual-outcomes-challenges-in-the-conduct-of-an-ebola-vaccine-trial-in-liberia-during-the-international-public-health-emergency
#11
Gregg S Larson, Beth R Baseler, Marie L Hoover, Jerome F Pierson, Jemee K Tegli, Melvin P Johnson, Mark W S Kieh, Laura A McNay, Wissedi Sio Njoh
Clinical trials are challenging endeavors. Planning and implementing an investigational vaccine trial in Liberia, in the midst of an Ebola virus disease (EVD) epidemic that World Health Organization classified a public health emergency of international concern, presented extraordinary challenges. Normally, years of preparation and a litany of tasks lay the groundwork for a successful, randomized, blinded, placebo-controlled trial focused on safety and efficacy. Difficult research settings, unpredictable events, and other unique circumstances can add complexity...
July 2017: American Journal of Tropical Medicine and Hygiene
https://www.readbyqxmd.com/read/28716555/attitudes-about-vaccines-to-prevent-ebola-virus-disease-in-guinea-at-the-end-of-a-large-ebola-epidemic-results-of-a-national-household-survey
#12
Kathleen L Irwin, Mohamed F Jalloh, Jamaica Corker, Barry Alpha Mahmoud, Susan J Robinson, Wenshu Li, Nyuma E James, Musa Sellu, Mohammad B Jalloh, Alpha Ahmadou Diallo, LaRee Tracy, Rana Hajjeh, Amanda VanSteelandt, Rebecca Bunnell, Lise Martel, Pratima L Raghunathan, Barbara Marston
INTRODUCTION: In 2014-2016, an Ebola epidemic devastated Guinea; more than 3800 cases and 2500 deaths were reported to the World Health Organization. In August 2015, as the epidemic waned and clinical trials of an experimental, Ebola vaccine continued in Guinea and neighboring Sierra Leone, we conducted a national household survey about Ebola-related knowledge, attitudes, and practices (KAP) and opinions about "hypothetical" Ebola vaccines. METHODS: Using cluster-randomized sampling, we selected participants aged 15+ years old in Guinea's 8 administrative regions, which had varied cumulative case counts...
July 14, 2017: Vaccine
https://www.readbyqxmd.com/read/28715541/cerebrospinal-fluid-examination-in-survivors-of-ebola-virus-disease
#13
Bridgette Jeanne Billioux, Avindra Nath, Eric J Stavale, Joseph Dorbor, Mosoka P Fallah, Michael C Sneller, Bryan R Smith
No abstract text is available yet for this article.
July 17, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/28715405/identification-and-pathological-characterization-of-persistent-asymptomatic-ebola-virus-infection-in-rhesus-monkeys
#14
Xiankun Zeng, Candace D Blancett, Keith A Koistinen, Christopher W Schellhase, Jeremy J Bearss, Sheli R Radoshitzky, Shelley P Honnold, Taylor B Chance, Travis K Warren, Jeffrey W Froude, Kathleen A Cashman, John M Dye, Sina Bavari, Gustavo Palacios, Jens H Kuhn, Mei G Sun
Ebola virus (EBOV) persistence in asymptomatic humans and Ebola virus disease (EVD) sequelae have emerged as significant public health concerns since the 2013-2016 EVD outbreak in Western Africa. Until now, studying how EBOV disseminates into and persists in immune-privileged sites was impossible due to the absence of a suitable animal model. Here, we detect persistent EBOV replication coinciding with systematic inflammatory responses in otherwise asymptomatic rhesus monkeys that had survived infection in the absence of or after treatment with candidate medical countermeasures...
July 17, 2017: Nature Microbiology
https://www.readbyqxmd.com/read/28710692/host-factors-involved-in-ebola-virus-replication
#15
Angela L Rasmussen
Ebola virus (EBOV) is a highly pathogenic emerging virus that represents a serious threat to global public health and a major priority for biodefense. The 2014 West African outbreak demonstrated the potential of EBOV to cause an epidemic affecting thousands of people. The severity of disease and high case fatality rate of EBOV is largely due to the host response elicited by the virus. EBOV infection hijacks a number of host pathways to carry out replication and stimulate potent inflammatory responses, while simultaneously subverting the host antiviral immune response...
July 15, 2017: Current Topics in Microbiology and Immunology
https://www.readbyqxmd.com/read/28709136/tetracyclines-as-a-potential-antiviral-therapy-against-crimean-congo-hemorrhagic-fever-virus-docking-and-molecular-dynamic-studies
#16
Amirhossein Sharifi, Arash Amanlou, Faezeh Moosavi-Movahedi, Sahand Golestanian, Massoud Amanlou
Crimean-Congo Hemorrhagic Fever Virus (CCHFV) is one of the deadliest human diseases with mortality rate near 50%. Special attention should be paid to this virus since there is no approved treatment for it. On the other hand, the recent outbreak of Ebola virus which is a member of hemorrhagic fever viruses shows this group of viruses can be extremely dangerous. Previous studies have indicated that nucleoprotein of CCHFV, a pivotal protein in virus replication, is an appropriate target for antiviral drug development...
July 1, 2017: Computational Biology and Chemistry
https://www.readbyqxmd.com/read/28708962/open-label-phase-i-clinical-trial-of-ad5-ebov-in-africans-in-china
#17
Lihua Wu, Zhe Zhang, Hainv Gao, Yuhua Li, Lihua Hou, Hangping Yao, Shipo Wu, Jian Liu, Ling Wang, You Zhai, Huilin Ou, Meihua Lin, Xiaoxin Wu, Jingjing Liu, Guanjing Lang, Qian Xin, Guolan Wu, Li Luo, Pei Liu, Jianzhong Shentu, Nanping Wu, Jifang Sheng, Yunqing Qiu, Wei Chen, Lanjuan Li
BACKGROUND: To determine the safety and immunogenicity of a novel recombinant adenovirus type 5 vector based Ebola virus disease vaccine (Ad5-EBOV) in Africans in China. METHODS: A phase 1, dose-escalation, open-label trial was conducted. 61 healthy Africans were sequentially enrolled, with 31 participants receiving one shot intramuscular injection and 30 participants receiving a double-shot regimen. Primary and secondary end points related to safety and immunogenicity were assessed within 28 days after vaccination...
July 14, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28701168/erratum-to-ethics-review-of-studies-during-public-health-emergencies-the-experience-of-the-who-ethics-review-committee-during-the-ebola-virus-disease-epidemic
#18
Emilie Alirol, Annette C Kuesel, Maria Magdalena Guraiib, Vânia de la Fuente-Núñez, Abha Saxena, Melba F Gomes
No abstract text is available yet for this article.
July 12, 2017: BMC Medical Ethics
https://www.readbyqxmd.com/read/28698624/naringenin-impairs-two-pore-channel-2-activity-and-inhibits-vegf-induced-angiogenesis
#19
Irene Pafumi, Margherita Festa, Francesca Papacci, Laura Lagostena, Cristina Giunta, Vijay Gutla, Laura Cornara, Annarita Favia, Fioretta Palombi, Franco Gambale, Antonio Filippini, Armando Carpaneto
Our research introduces the natural flavonoid naringenin as a novel inhibitor of an emerging class of intracellular channels, Two-Pore Channel 2 (TPC2), as shown by electrophysiological evidence in a heterologous system, i.e. Arabidopsis vacuoles lacking endogenous TPCs. In view of the control exerted by TPC2 on intracellular calcium signaling, we demonstrated that naringenin dampens intracellular calcium responses of human endothelial cells stimulated with VEGF, histamine or NAADP-AM, but not with ATP or Angiopoietin-1 (negative controls)...
July 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28695835/the-concept-of-travel-medicine-and-the-actual-situation-of-travel-related-illnesses
#20
Varol Tunalı, Nevin Turgay
Travel medicine defines all diseases and medical situations that are related to travel. Travel medicine comprises infectious diseases, traumas, altitude sickness, sun burns, embolisms, jet lag, and many more travel-related situations. With the increasing possibility and ease of travel, the number of people who have travelled internationally has exceeded 1.13 billion in 2014, and the revenues of international travel have exceeded 1.25 trillion dollars. With every passing day, international travels are shifting toward the developing countries and to more exotic regions of the world, and travelers tend to be more adventurous and daring, thereby increasing risky behaviors during travels...
June 2017: Türkiye Parazitolojii Dergisi
keyword
keyword
40838
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"